Clinical Report: Correction to a Figure in the Vitiligo Consensus Statement

Overview

A figure in the international consensus statement on vitiligo severity and relapse contained an incorrect mathematical symbol in the central text box of its second row. The figure was corrected, and the article was updated online.

Background

The consensus statement, “Definition of Severity and Relapse for Vitiligo: An International Consensus Statement,” was published online on March 25, 2026, and appeared in the May 2026 issue. It addresses standardized definitions of vitiligo severity and relapse. The correction concerns a symbol in one figure and does not describe changes to the statement’s text or conclusions.

Data Highlights

The correction reports a figure-symbol change; no numerical or trial data are provided.

Key Findings

• The affected publication is the international consensus statement on definitions of vitiligo severity and relapse.
• The statement was published online March 25, 2026, and subsequently in the May 2026 issue.
• The error was in the central text box of the figure’s second row.
• The mathematical symbol in that box was corrected.
• The article has been corrected online.

Clinical Implications

The source reports a correction to a figure and does not specify changes to clinical recommendations or the consensus statement’s conclusions.

Conclusion

The correction addresses a mathematical symbol in one figure of the vitiligo consensus statement. The online article has been updated.

Related Resources & Content

1. JAMA Dermatology, JAMA Network, 2026 — Error in the Figure
2. International Consensus Statement, JAMA Dermatology, 2026 — Definition of Severity and Relapse for Vitiligo: An International Consensus Statement
3. Dermatology and Therapy — Amendment: An Expert Review of Long-Term Effectiveness of Biologics in Moderate-to-Severe Atopic Dermatitis Using Indirect Comparison Techniques
4. ADA News — Establishing standardized vitiligo relapse, severity criteria
5. ASCO Publications — Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study
6. MDSpire News — New Data Redefines Vitiligo Treatment Response Measures
7. Error in the Figure | JAMA Dermatology | JAMA Network
8. Definition of Severity and Relapse for Vitiligo: An International Consensus Statement
9. Error in the Figure | JAMA Dermatology | JAMA Network
10. Definition of Severity and Relapse for Vitiligo: An International Consensus Statement | Dermatology | JAMA Dermatology | JAMA Network
11. Definition of Severity and Relapse for Vitiligo: An International Consensus Statement - PubMed
12. Definition of severity and relapse for vitiligo -ORCA
13. Vitiligo Metrics Lack Multidimensional Severity Domains | Dermatology | JAMA Dermatology | JAMA Network
14. Diagnostik und Therapie der Vitiligo | Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V.
15. Core outcome set in vitiligo: perspectives from the frontline of research and publishing. What do trialists and editors of five leading dermatology journals really think?
16. Reliability of measurement instruments for vitiligo extent and their feasibility: A meta-analysis.
17. Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study | British Journal of Dermatology | Oxford Academic
18. Impact of treatment duration on response durability: A post hoc analysis of the double-blind, vehicle-controlled, randomized TRuE-V long-term extension study of ruxolitinib cream in vitiligo.